ATE532794T1 - Tripeptide als hemmer des hepatitis-c-virus - Google Patents

Tripeptide als hemmer des hepatitis-c-virus

Info

Publication number
ATE532794T1
ATE532794T1 AT06759490T AT06759490T ATE532794T1 AT E532794 T1 ATE532794 T1 AT E532794T1 AT 06759490 T AT06759490 T AT 06759490T AT 06759490 T AT06759490 T AT 06759490T AT E532794 T1 ATE532794 T1 AT E532794T1
Authority
AT
Austria
Prior art keywords
hepatitis
tripeptides
virus inhibitors
compounds
disclosed
Prior art date
Application number
AT06759490T
Other languages
English (en)
Inventor
Ny Sin
Paul Michael Scola
Nicholas A Meanwell
Xiangdong Alan Wang
Li-Qiang Sun
Jie Chen
Andrew Charles Good
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE532794T1 publication Critical patent/ATE532794T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT06759490T 2005-05-10 2006-05-10 Tripeptide als hemmer des hepatitis-c-virus ATE532794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67962805P 2005-05-10 2005-05-10
PCT/US2006/018078 WO2006122188A2 (en) 2005-05-10 2006-05-10 Tripeptides as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
ATE532794T1 true ATE532794T1 (de) 2011-11-15

Family

ID=37012073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759490T ATE532794T1 (de) 2005-05-10 2006-05-10 Tripeptide als hemmer des hepatitis-c-virus

Country Status (8)

Country Link
US (1) US7592336B2 (de)
EP (1) EP1879910B1 (de)
JP (1) JP4940231B2 (de)
CN (1) CN101228180B (de)
AT (1) ATE532794T1 (de)
ES (1) ES2374572T3 (de)
NO (1) NO20075616L (de)
WO (1) WO2006122188A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2041156T3 (en) 2006-07-13 2014-02-24 Achillion Pharmaceuticals Inc 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101652383B (zh) * 2006-11-16 2013-09-18 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008098368A1 (en) * 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibitors of hepatitis c ns3 protease
TWI395746B (zh) 2007-06-29 2013-05-11 Gilead Sciences Inc 抗病毒性化合物
CA2692145C (en) * 2007-06-29 2015-03-03 Gilead Sciences, Inc. Antiviral compounds
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
TW200932255A (en) * 2007-12-21 2009-08-01 Avila Therapeutics Inc HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TWI487522B (zh) 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Ｈｃｖ蛋白酶抑制劑及其用途（一）
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AR070413A1 (es) * 2008-02-04 2010-04-07 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de proteasa de serina
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (de) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
JP5615132B2 (ja) * 2010-11-05 2014-10-29 住友精化株式会社 高純度シクロプロパンスルホンアミドの製造方法
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (de) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (de) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hemmer des hepatitis-c-virus
EP2970195B1 (de) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Verfahren zur herstellung von sovaprevir
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN105348144B (zh) * 2015-12-01 2018-01-09 江西善渊药业有限公司 一种(1r,2s)‑1‑氨基‑2‑乙烯基环丙烷羧酸乙酯的合成方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
DK1003775T3 (da) 1997-08-11 2005-05-30 Boehringer Ingelheim Ca Ltd Hepatitis C-inhibitorpeptider
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
EP1506172B1 (de) * 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
JP4682140B2 (ja) 2003-03-05 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類縁体
EP1601685A1 (de) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis-c-inhibitierende verbindungen
WO2004093915A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
EP1629000B1 (de) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
AU2004231987C1 (en) 2003-04-18 2010-09-30 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2522577C (en) 2003-05-21 2011-04-26 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
UY28525A1 (es) 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
AU2004282148A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
BRPI0506948B1 (pt) 2004-01-30 2018-09-18 Medivir Ab inibidores de serina protease ns-3 de hcv
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
WO2006016930A2 (en) 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
EP1763531A4 (de) 2004-06-28 2009-07-01 Boehringer Ingelheim Int Analoga von hepatitis-c inhibierenden peptiden
PT1778702E (pt) 2004-07-16 2011-10-18 Gilead Sciences Inc Compostos antivirais
ES2366478T3 (es) 2004-07-20 2011-10-20 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
EP1797111B1 (de) 2004-08-27 2011-06-22 Schering Corporation Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2006033878A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
JP2008517896A (ja) 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2439732T3 (es) 2005-03-08 2014-01-24 Boehringer Ingelheim International Gmbh Procedimiento para preparar compuestos macrocíclicos
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors

Also Published As

Publication number Publication date
EP1879910B1 (de) 2011-11-09
CN101228180B (zh) 2011-03-09
US20080152619A1 (en) 2008-06-26
EP1879910A2 (de) 2008-01-23
JP4940231B2 (ja) 2012-05-30
CN101228180A (zh) 2008-07-23
WO2006122188A3 (en) 2007-03-08
ES2374572T3 (es) 2012-02-17
NO20075616L (no) 2008-01-30
US7592336B2 (en) 2009-09-22
JP2008540555A (ja) 2008-11-20
WO2006122188A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE532794T1 (de) Tripeptide als hemmer des hepatitis-c-virus
ATE546460T1 (de) Hemmer des hepatitis-c-virus
ATE492558T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
ATE492559T1 (de) Makrocyclische peptide als hepatitis-c-virus- hemmer
EA200900676A1 (ru) Ингибиторы вируса гепатита с
ATE547103T1 (de) Hemmer des hepatitis-c-virus
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
JO2593B1 (en) Protease inhibitors NS3 hepatitis C HCV virus
WO2008008776A3 (en) Hepatitis c virus inhibitors
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20091706L (no) Inhibitorer av hepatitt C virus
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
EA201101240A1 (ru) Ингибиторы вируса гепатита с
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
ATE474827T1 (de) Hcv-replikationshemmer
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
WO2008057871A3 (en) Inhibitors of hepatitis c virus
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
UA95990C2 (en) Hcv ns3 protease inhibitors